GenScript Biotech: Associate Legend Achieves 100% ORR with First-in-Class Dual-Targeting CAR-T LB2501 in Early B-NHL Trial

Bulletin Express06-14

GenScript Biotech Corporation (GenScript; HKEX: 01548) announced that its U.S.-listed associate, Legend Biotech Corporation (Legend), has delivered initial clinical proof-of-concept for LB2501, an investigational in vivo CD19/CD20 dual-targeting CAR-T therapy, in relapsed or refractory B-cell non-Hodgkin lymphoma (R/R B-NHL).

Legend’s Phase 1 data, released on 14 June 2026 and presented at the European Hematology Association 2026 Congress (Abstract #LB5006), show:

• Efficacy: A single infusion at the higher dose level (DL2) produced a 100% objective response rate (6/6 patients) and an 83.33% complete response rate (5/6 patients). All responses were ongoing at the data cutoff.

• Pharmacodynamics: LB2501 achieved dose-dependent in vivo CAR-T expansion without the need for lymphodepletion.

• Safety: No dose-limiting toxicities, serious adverse events, immune effector cell-associated neurotoxicity syndrome, or deaths were reported.

The announcement underscores LB2501’s potential as a first-in-class, in vivo, dual-targeting CAR-T approach for R/R B-NHL, while maintaining a favorable safety profile in the early-stage study.

GenScript cautions shareholders and prospective investors to remain mindful of investment risks when dealing in its securities. Further details are available in Legend’s press release on its investor relations website.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1185416550?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-14 18:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1185416550","market":"hk","top_or_hot":-1,"title":"GenScript Biotech: Associate Legend Achieves 100% ORR with First-in-Class Dual-Targeting CAR-T LB2501 in Early B-NHL Trial","media":"Bulletin Express","content":"<p>GenScript Biotech Corporation (GenScript; HKEX: 01548) announced that its U.S.-listed associate, Legend Biotech Corporation (Legend), has delivered initial clinical proof-of-concept for LB2501, an investigational in vivo CD19/CD20 dual-targeting CAR-T therapy, in relapsed or refractory B-cell non-Hodgkin lymphoma (R/R B-NHL).</p>\n<p>Legend’s Phase 1 data, released on 14 June 2026 and presented at the European Hematology Association 2026 Congress (Abstract #LB5006), show:</p>\n<p>• Efficacy: A single infusion at the higher dose level (DL2) produced a 100% objective response rate (6/6 patients) and an 83.33% complete response rate (5/6 patients). All responses were ongoing at the data cutoff.</p>\n<p>• Pharmacodynamics: LB2501 achieved dose-dependent in vivo CAR-T expansion without the need for lymphodepletion.</p>\n<p>• Safety: No dose-limiting toxicities, serious adverse events, immune effector cell-associated neurotoxicity syndrome, or deaths were reported.</p>\n<p>The announcement underscores LB2501’s potential as a first-in-class, in vivo, dual-targeting CAR-T approach for R/R B-NHL, while maintaining a favorable safety profile in the early-stage study.</p>\n<p>GenScript cautions shareholders and prospective investors to remain mindful of investment risks when dealing in its securities. Further details are available in Legend’s press release on its investor relations website.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GenScript Biotech: Associate Legend Achieves 100% ORR with First-in-Class Dual-Targeting CAR-T LB2501 in Early B-NHL Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGenScript Biotech: Associate Legend Achieves 100% ORR with First-in-Class Dual-Targeting CAR-T LB2501 in Early B-NHL Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-06-14 18:21</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>GenScript Biotech Corporation (GenScript; HKEX: 01548) announced that its U.S.-listed associate, Legend Biotech Corporation (Legend), has delivered initial clinical proof-of-concept for LB2501, an investigational in vivo CD19/CD20 dual-targeting CAR-T therapy, in relapsed or refractory B-cell non-Hodgkin lymphoma (R/R B-NHL).</p>\n<p>Legend’s Phase 1 data, released on 14 June 2026 and presented at the European Hematology Association 2026 Congress (Abstract #LB5006), show:</p>\n<p>• Efficacy: A single infusion at the higher dose level (DL2) produced a 100% objective response rate (6/6 patients) and an 83.33% complete response rate (5/6 patients). All responses were ongoing at the data cutoff.</p>\n<p>• Pharmacodynamics: LB2501 achieved dose-dependent in vivo CAR-T expansion without the need for lymphodepletion.</p>\n<p>• Safety: No dose-limiting toxicities, serious adverse events, immune effector cell-associated neurotoxicity syndrome, or deaths were reported.</p>\n<p>The announcement underscores LB2501’s potential as a first-in-class, in vivo, dual-targeting CAR-T approach for R/R B-NHL, while maintaining a favorable safety profile in the early-stage study.</p>\n<p>GenScript cautions shareholders and prospective investors to remain mindful of investment risks when dealing in its securities. Further details are available in Legend’s press release on its investor relations website.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01548","symbol_name":"金斯瑞生物科技","start_time":0,"source_url":"","article_id":"1185416550","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1185416550","pubTimestamp":1781432504,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"GenScript Biotech Corporation (GenScript; HKEX: 01548) announced that its U.S.-listed associate, Legend Biotech Corporation (Legend), has delivered initial clinical proof-of-concept for LB2501, an...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01548":"金斯瑞生物科技"},"translate_title":"金斯瑞生物：Associate Legend在早期B-NHL试验中使用同类首创的双靶向CAR-T LB2501实现100%ORR","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01548":1},"content_text":"GenScript Biotech Corporation (GenScript; HKEX: 01548) announced that its U.S.-listed associate, Legend Biotech Corporation (Legend), has delivered initial clinical proof-of-concept for LB2501, an investigational in vivo CD19/CD20 dual-targeting CAR-T therapy, in relapsed or refractory B-cell non-Hodgkin lymphoma (R/R B-NHL).\nLegend’s Phase 1 data, released on 14 June 2026 and presented at the European Hematology Association 2026 Congress (Abstract #LB5006), show:\n• Efficacy: A single infusion at the higher dose level (DL2) produced a 100% objective response rate (6/6 patients) and an 83.33% complete response rate (5/6 patients). All responses were ongoing at the data cutoff.\n• Pharmacodynamics: LB2501 achieved dose-dependent in vivo CAR-T expansion without the need for lymphodepletion.\n• Safety: No dose-limiting toxicities, serious adverse events, immune effector cell-associated neurotoxicity syndrome, or deaths were reported.\nThe announcement underscores LB2501’s potential as a first-in-class, in vivo, dual-targeting CAR-T approach for R/R B-NHL, while maintaining a favorable safety profile in the early-stage study.\nGenScript cautions shareholders and prospective investors to remain mindful of investment risks when dealing in its securities. Further details are available in Legend’s press release on its investor relations website.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"productRelease,dataReport,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1185416550","isCrawlerRequest":true}